Is Biopharma Bottoming?

Several life sciences hedge funds posted strong gains in June.

Carsten Snejbjerg/Bloomberg

Carsten Snejbjerg/Bloomberg

A number of ailing life sciences hedge funds showed some improvement last month.

Investors probably shouldn’t get too excited, however. Many of these funds are still very sickly, with losses ranging from 30 percent to more than 60 percent this year alone, on top of the sharp losses suffered in 2021.


To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.